US Primary Aldosteronism Market Research Report: By Diagnosis (blood test, imaging) - Forecast to 2035

US Primary Aldosteronism Market Overview

As per MRFR analysis, the US Primary Aldosteronism Market Size was estimated at 258.3 (USD Million) in 2023. The US Primary Aldosteronism Market Industry is expected to grow from 330(USD Million) in 2024 to 740 (USD Million) by 2035. The US Primary Aldosteronism Market CAGR (growth rate) is expected to be around 7.618% during the forecast period (2025 - 2035).

Key US Primary Aldosteronism Market Trends Highlighted

The US Primary Aldosteronism Market is experiencing a notable shift driven by increased awareness and diagnosis of the condition. As healthcare providers focus on identifying diseases that lead to hypertension, more cases of primary aldosteronism are being detected. This has led to a greater demand for advanced diagnostic tools and treatment options tailored for this specific disorder.

The growing emphasis on personalized medicine is a key market driver, with healthcare systems looking to provide targeted therapies that cater to individual patient needs. Opportunities in the US market can be captured by further investment in innovative treatment methods and technologies. There is a rising interest in developing new pharmacological therapies, including mineralocorticoid receptor antagonists, which show promise in treating primary aldosteronism effectively.

Furthermore, as public health campaigns aim to educate the population about the risks associated with untreated hypertension and its links to primary aldosteronism, there is potential for increased screening and early intervention. In recent times, the trend of integrating telemedicine into patient care has gained traction in the US, particularly in follow-up consultations for patients with primary aldosteronism. This technology allows for efficient monitoring and management of patients, further enhancing treatment adherence and improving health outcomes.

The ongoing research initiatives funded by governmental health bodies also suggest a commitment to better understand this endocrine disorder, indicating sustained growth and innovation in the US Primary Aldosteronism Market.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

US Primary Aldosteronism Market Drivers

Rising Prevalence of Primary Aldosteronism

The US Primary Aldosteronism Market Industry is experiencing growth driven by the increasing prevalence of primary aldosteronism in the population. According to the American Heart Association, nearly 10% of patients with hypertension may have primary aldosteronism, translating to approximately 6 million individuals in the United States. This surge in cases has propelled the demand for diagnostic tests and treatment options for this condition.

Necessitating more comprehensive approaches to management, healthcare providers and pharmaceutical companies are investing in innovative treatment methods. The National Institutes of Health has also recognized primary aldosteronism as a significant factor influencing hypertension, frequently advocating for improved awareness and diagnostic protocols. As a result, more patients are being diagnosed and treated, contributing positively to the growth of the US Primary Aldosteronism Market.

Technological Advancements in Diagnostic Methods

Advancements in diagnostic technologies are significantly impacting the US Primary Aldosteronism Market Industry. Innovations such as enhanced blood tests and imaging technologies have made diagnosing primary aldosteronism more accurate and efficient. The American College of Cardiology has highlighted that the introduction of new non-invasive diagnostic tools has facilitated early detection, leading to timely treatment interventions.

Data from healthcare research suggests that accuracy rates in diagnosing primary aldosteronism have improved by 30% with these new methods. This trend not only benefits patients but also encourages healthcare providers and pharmaceutical companies to focus on developing novel therapies, thereby promoting market growth.

Increased Research and Development Efforts

Investments in Research and Development (R&D) aimed at understanding primary aldosteronism are a key driver for the US Primary Aldosteronism Market Industry. Major pharmaceutical companies are channeling significant funding into R&D to develop effective medication and treatment options. According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately $6 billion is allocated annually to study endocrine disorders, including primary aldosteronism.

With the ongoing emphasis on precision medicine, these studies are crucial in identifying genetic factors and tailored therapies, which supports better outcomes for affected individuals and consequently enhances market viability.

Growing Awareness of Endocrine Disorders

Public awareness regarding endocrine disorders, including primary aldosteronism, is on the rise in the US. Organizations such as the Endocrine Society have been active in educating the public and healthcare professionals about the importance of diagnosing and treating hormonal imbalances. Recent surveys indicate a 25% increase in public knowledge of the symptoms associated with primary aldosteronism over the past five years.

This increase in awareness not only helps in early diagnosis but also drives patients to seek medical help, thereby creating higher demand for treatments and diagnostic services in the US Primary Aldosteronism Market Industry.

US Primary Aldosteronism Market Segment Insights

Primary Aldosteronism Market Diagnosis Insights

The Diagnosis segment of the US Primary Aldosteronism Market plays a crucial role in identifying and managing this condition effectively. As the market grows in response to increasing awareness and understanding of Primary Aldosteronism, there is an emphasis on various diagnostic methods, primarily blood tests and imaging techniques.

Blood tests are vital for measuring aldosterone levels and the renin-angiotensin-aldosterone system, with timely and accurate results directly impacting treatment plans for patients. Imaging techniques, including computed tomography (CT) scans and magnetic resonance imaging (MRI), are significant for locating adrenal tumors, further influencing treatment decisions.

The integration of innovative technologies is advancing diagnostic accuracy and efficiency, aligning with the broader trends in the healthcare industry toward personalized medicine. Furthermore, the push for early diagnosis is driven by the rising prevalence of hypertension and cardiovascular diseases in the US. As more individuals are screened and diagnosed, healthcare providers are likely to enhance their diagnostic capabilities, creating opportunities for growth within this segment.

Moreover, the growing reliance on advanced imaging modalities is indicative of a shift towards improved patient outcomes, reinforcing the importance of this segment in the overall management of Primary Aldosteronism. Overall, the Diagnosis segment is integral to the US Primary Aldosteronism Market, ensuring that patients receive appropriate interventions based on accurate and timely assessments.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

US Primary Aldosteronism Market Key Players and Competitive Insights

The US Primary Aldosteronism Market has garnered significant attention in recent years due to the rising awareness of this condition and the increasing prevalence of hypertension associated with aldosterone excess. This market is characterized by a growing demand for diagnostic and therapeutic solutions, leading to heightened competition among key players. Companies are focusing on research and development efforts to introduce innovative therapies while navigating the regulatory landscape, which has become more conducive for the approval of new treatments.

The competitive environment is further fueled by partnerships and collaborations aimed at enhancing product portfolios, improving market penetration, and ultimately, addressing the unmet medical needs in the management of Primary Aldosteronism within the United States.

Merck and Co is established as a robust player in the US Primary Aldosteronism Market, bringing a strong research and development background that is crucial for addressing this complex condition. The company has leveraged its vast experience and expertise in the pharmaceutical sector to develop effective treatment options that meet the specific needs of patients with Primary Aldosteronism. Merck and Co's strengths lie in its comprehensive pipeline of innovative therapies, which are supported by rigorous clinical trials and data-driven approaches.

The company's commitment to patient-centric solutions and its strategic collaborations have enabled it to maintain a significant market presence, fueling ongoing growth in this competitive landscape.

On the other hand, Bristol Myers Squibb has made a notable impact in the US Primary Aldosteronism Market with its strong focus on specialized therapeutics. The company boasts a portfolio of key products that effectively address the challenges associated with this condition, while also promoting awareness and education regarding the complications of untreated aldosterone excess. Bristol Myers Squibb has a solid market presence driven by its investments in research and targeted therapies, which has helped the company foster relationships within the healthcare community.

In addition to its impactful product offerings, Bristol Myers Squibb has pursued mergers and acquisitions strategically to expand its capabilities and enhance its competitive edge. This approach not only strengthens Bristol Myers Squibb's position but also contributes to the continuous evolution of treatment options available to patients, thereby solidifying its role in this niche market.

Key Companies in the US Primary Aldosteronism Market Include

• Merck and Co


• Bristol Myers Squibb


• AstraZeneca


• Novartis


• Eli Lilly


• GlaxoSmithKline


• Daiichi Sankyo


• Baxter International


• Pfizer


• Amgen


• AbbVie


• Roche


• Sanofi


• Johnson and Johnson


• Teva Pharmaceuticals

US Primary Aldosteronism Market Industry Developments

In the US Primary Aldosteronism Market, recent developments have focused on advancements in drug treatments and increased awareness regarding the condition. Companies like Merck and Co, Bristol Myers Squibb, AstraZeneca, and Novartis are actively working on Research and Development initiatives to enhance patient outcomes through innovative therapies.

Notably, in October 2022, Merck announced progress in their aldosterone antagonist that shows promise in treating resistant hypertension associated with Primary Aldosteronism. Additionally, in March 2023, AstraZeneca launched a new campaign aimed at early diagnosis of Primary Aldosteronism, acknowledging the underdiagnosis of this condition in hypertensive patients.

Furthermore, recent market analysis indicates a significant increase in the market valuation due to rising prevalence rates and effective treatment options. The market has been further bolstered by the emphasis on personalized medicine and the development of new diagnostic tools. In terms of mergers and acquisitions, no significant transactions involving the listed companies have been reported recently that pertain to Primary Aldosteronism.

The ongoing collaborations and partnerships among these leading pharmaceutical firms signal a strong commitment to expanding their presence in this therapeutic area.

US Primary Aldosteronism Market Segmentation Insights

Primary Aldosteronism Market Diagnosis Outlook

• blood test


• imaging

Report Scope:

Report Attribute/Metric Source:	Details
MARKET SIZE 2018	258.3(USD Million)
MARKET SIZE 2024	330.0(USD Million)
MARKET SIZE 2035	740.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	7.618% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Merck and Co, Bristol Myers Squibb, AstraZeneca, Novartis, Eli Lilly, GlaxoSmithKline, Daiichi Sankyo, Baxter International, Pfizer, Amgen, AbbVie, Roche, Sanofi, Johnson and Johnson, Teva Pharmaceuticals
SEGMENTS COVERED	Diagnosis
KEY MARKET OPPORTUNITIES	Increasing prevalence of undiagnosed cases, Growth in diagnostic innovations, Rising awareness of hormonal disorders, Enhanced treatment options availability, Expansion of patient support programs
KEY MARKET DYNAMICS	growing patient awareness, increased diagnostic capabilities, rising treatment options, aging population, healthcare reimbursement policies
COUNTRIES COVERED	US